2018年~2020年南京地区新型抗肿瘤药物利用分析

Usage of New Anti-cancer Drugs in Nanjing from 2018 to 2020

目的分析2018年~2020年南京地区的新型抗肿瘤药物利用情况和发展趋势,为临床合理利用和国家医保准入提供参考。方法基于江苏省医药情报研究所提供的南京地区2018年~2020年抗肿瘤药物的采购数据,采用药物利用频度(DDDs)、用药金额、限定日费用(DDDc)、排序比(B/A)等指标进行回顾性统计分析。结果新型抗肿瘤药物用药金额及构成比不断增加;药物利用频度快速增长,PD1类药物利用频度增速明显;DDDc呈下降趋势,单抗类药物DDDc普遍偏高;B/A总体上升,药物同步性转好。结论南京地区新型抗肿瘤药物利用呈上升趋势,并陆续进入医保目录,可及性、可负担性显著提高,新型抗肿瘤药物的合理利用得到进一步加强。

Objective To analyze the data on procurement of new anti-cancer drugs in Nanjing between 2018 and 2020 and find out about the recent usage of such drugs and developments in order to provide reference for clinical rational use of new anti-cancer drugs and national medical insurance admittance.Methods Based on the procurement data by Jiangsu Institute of Medical Information in Nanjing from 2018 to 2020,the DDDs,consumption amount,defined daily dose cost(DDDc)and B/A value were retrospectively analyzed.Results The consumption amount and constituent ratio of new anti-cancer drugs continued to rise.DDDs increased rapidly,the DDDs of PD1 drugs increased significantly,but DDDc of most of these drugs continued downward.The DDDc of most monoclonal antibody drugs was high.The B/A values of most drugs were elevated while drug synchronization improved.Conclusion The usage of new anti-cancer drugs is on the increase,and these drugs are entering the medical insurance directory one after another.The availability and affordability of new anti-cancer drugs have been significantly improved.These drugs are being used more rationally.